All In MedTech

FDA Clearance Tracker · P810025-S021

AMVISC AND AMVISC PLUS SODIUM HYALURONATE VISCOELASTICS

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Dec 3, 2002 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Dec 3, 2002

Approved

Time to decision

207 days

Received May 10, 2002. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P810025-S021
Device name
AMVISC AND AMVISC PLUS SODIUM HYALURONATE VISCOELASTICS
Applicant location
Irvine, CA
Received
May 10, 2002
Decided
Dec 3, 2002
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P810025

Device type

Device class
Class III
Regulation
21 CFR 886.4275
Specialty
Ophthalmology

Every decision under product code LZP

FDA's approval statement

As written in FDA's record.

APPROVAL FOR A BUFFERED FORMULATION (PH 6.8 - 7.6) FOR AMVISC AND AMVISC PLUS SODIUM HYALURONATE VISCOELASTICS.

Source documents

Other decisions for Bausch & Lomb, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.